Contravisory Investment Management Inc. Has $9.30 Million Stock Position in Merck & Co., Inc. $MRK

Contravisory Investment Management Inc. increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 9.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 77,298 shares of the company’s stock after buying an additional 6,385 shares during the period. Merck & Co., Inc. accounts for about 1.9% of Contravisory Investment Management Inc.’s portfolio, making the stock its 13th largest holding. Contravisory Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $9,298,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. during the fourth quarter worth about $25,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. in the 4th quarter worth about $26,000. Abound Financial LLC bought a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. IFC & Insurance Marketing Inc. bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $31,000. Finally, High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $125.36 on Friday. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $125.96. The stock has a market cap of $309.61 billion, a PE ratio of 35.31, a price-to-earnings-growth ratio of 2.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The stock has a fifty day moving average of $115.88 and a 200-day moving average of $114.23.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. Merck & Co., Inc.’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The European Commission approved Keytruda plus Padcev for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer, expanding Merck’s oncology franchise in Europe. European Commission Approves KEYTRUDA Plus Padcev
• Positive Sentiment: The FDA approved Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1-positive advanced triple-negative breast cancer, adding another growth opportunity for the drug. FDA Approves Keytruda and Trodelvy for TNBC
• Positive Sentiment: Analyst commentary has also been supportive, with CICC Research initiating coverage at outperform and a price target above the recent trading range, reinforcing bullish sentiment around the stock. Merck Coverage Update
• Neutral Sentiment: Other reports noted that competitor Gilead won EC approval to expand Trodelvy’s label in metastatic TNBC, which is relevant to Merck because Trodelvy is part of the newly approved Keytruda combination, but the net market impact is still unclear. Gilead Wins EC Approval to Expand Trodelvy’s Label
• Neutral Sentiment: Several analyst notes were mixed, including Citi’s hold rating and Scotiabank’s buy rating, suggesting the latest move is being driven more by product news than by a major change in analyst consensus. Citi Keeps Their Hold Rating on Merck & Company

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. JPMorgan Chase & Co. upped their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $128.72.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.